CD274 and neoplasm: MN-siPDL1 incorporates a nanoparticle carrier that is delivered with high efficiency to tumor cells in vivo11–19, where it post-transcriptionally inhibits PD-L1 expression on tumor cells via the RNA interference mechanism.